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Abstract
Introduction Relaxin levels are increased in cases of human
breast cancer and has been shown to promote cancer cell
migration in carcinoma cells of the breast, prostate gland and
thyroid gland. In oestrogen receptor alpha-negative MDA-MB-
231 human breast cancer cells, relaxin was shown to down-
regulate the metastasis-promoting protein S100A4
(metastasin), a highly significant prognostic factor for poor
survival in breast cancer patients. The cellular mechanisms of
relaxin exposure in breast cancer cells are not fully understood.
The aim of this study was to investigate short-term and long-term
effects of relaxin on cancer cell motility and S100A4 expression
and to determine the long-term effects of relaxin on in vivo
tumour growth in an oestrogen-independent context.
Method We have established stable transfectants of highly
invasive oestrogen-receptor alpha-negative MDA-MB-231
human breast cancer cells with constitutive expression of
bioactive H2-relaxin (MDA/RLN2). RLN2 secretion was
determined by ELISA. Relaxin receptor RXFP1 (Relaxin-family-
peptide) was detected by reverse transcription (RT) PCR and its
activation was assessed by induction of cyclic adenosine
monophosphate (cAMP). Stable MDA/RLN2 clones and RLN2
treated MDA-MB-231 cells were subjected to motility and in
vitro-invasion assays. Proliferation was assessed in
bromodeoxyuridine (BrdU) and MTT assays. S100A4
expression was determined by RT-PCR and Western blot.
Specific small interfering RNA was employed to down-regulate
relaxin receptor and S100A4. MDA/EGFP vector control and
two MDA/RLN2 clones were injected subcutaneously in nude
mice to determine tumour growth and cancer cell invasiveness
in vivo. Xenograft tumour tissues were assessed by histology
and immunohistochemistry and frozen tissues were used for the
detection of S100A4 and RLN2.
Results Short-term exposure to relaxin for 24 hours increased
cell motility in a relaxin receptor-dependent manner. This
increase in cell motility was mediated by S100A4. Long-term
exposure to relaxin secreted from stable transfectants reduced
cell motility and in vitro invasiveness. Relaxin decreased cell
proliferation and down-regulated cellular S100A4 levels in
MDA-MB-231 and T47D breast cancer cells. Stable MDA/
RLN2 transfectants produced smaller xenograft tumours
containing reduced S100A4 protein levels in vivo.
Conclusion Our results indicate that long-term exposure to
relaxin confers growth inhibitory and anti-invasive properties in
oestrogen-independent tumours in vivo, which may in part be
mediated through a down-regulation of S100A4.
Introduction
The polypeptide hormone relaxin is increased in human breast
carcinoma tissues [1]. In all human breast tumours investi-
gated, immunoreactive H2 relaxin (RLN2) was localised to the
cytoplasm of neoplastic epithelial cells [1]. The expression of
RLN1 and RLN2 genes in neoplastic breast tissues demon-
strated the local production of relaxin in breast carcinoma [1].
Relaxin was also shown to be increased in human carcinoma
of the prostate gland [2], endometrium [3] and thyroid gland
[4,5].
BrdU = bromodeoxyuridine; cAMP = cyclic adenosine monophosphate; ERα = oestrogen receptor-alpha; FCS = fetal calf serum; IBMX = 3-isobutyl-
1-methyl-xanthine; PBS = phosphate buffered saline; rhRLN = recombinant human RLN; RLN2 = H2 relaxin; RT-PCR = reverse transcriptase 
polymerase chain reaction; RXFP1 = relaxin/insulin-like family peptide receptor 1 (formerly: LGR7 = leucin-rich G protein-coupled receptor 7); siRNA 
= small interfering RNA; TUNEL = dUTP nick end labelling.Breast Cancer Research    Vol 10 No 4    Radestock et al.
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In addition, the breast is a physiological producer and target
for relaxin and mammary epithelial cells, and myoepithelial cells
in normal human breast tissue of prepubertal and all ages of
adult women were shown to produce relaxin [1,6,7]. Apart
from placental production during pregnancy [8,9], relaxin was
not detectable in the plasma of cycling and lactating women
suggesting local production and autocrine/paracrine actions
of relaxin within the glandular breast tissue. The recently
reported elevated relaxin serum levels in women with meta-
static breast cancer suggest that relaxin may be a novel marker
associated with breast cancer metastasis [10]. Relaxin binds
predominantly to the 7-transmembrane G-protein-coupled
receptor LGR7 [11-13], also known as the relaxin/insulin-like
family peptide receptor 1 (RXFP1) [14]. Activation of RXFP1
by relaxin caused elevation of cyclic adenosine monophos-
phate (cAMP) levels [15,16]. In vitro studies have linked
relaxin expression with invasive behaviour of cancer cells
[4,17-19]. With treatment with porcine relaxin, SK-BR3 and
MCF-7 human breast cancer cells showed increased secre-
tion of MMP-2, MMP-9 and MMP-7 causing increased migra-
tion through matrigel [19]. Adenoviral-mediated expression of
human prorelaxin in CF33.MT canine mammary carcinoma
cells was described to enhance in vitro invasiveness through
a laminin matrix [20]. Whether these pro-migratory effects of
relaxin were mediated by RXFP1 is unknown. Earlier studies
have also reported that porcine relaxin reduces proliferation
and induces differentiation in the oestrogen receptor-alpha
(ERα)-positive breast cancer cell line MCF-7 in vitro [21,22]
and in vivo [23]. Until now, these conflicting actions of relaxin
in breast cancer cells have not been fully understood.
Although in vivo studies in rat uterus have provided evidence
for a crosstalk between RXFP1 and ERα and demonstrated
ERα-mediated oestrogenic effects with relaxin treatment
[24,25], a direct oestrogenic action of relaxin in breast cancer
has not been described. Oestrogen-independent breast can-
cer usually shows a more aggressive clinical course and
poorer treatment responses. Currently, little information is
available on the role of relaxin in ERα-negative human breast
cancer cells.
We have previously identified the EF-hand (helix-turn-helix
structural domain) calcium-binding protein S100A4 (metasta-
sin) as a relaxin target in oestrogen-independent, ERα-nega-
tive, highly invasive MDA-MB-231 human breast cancer cells
[26]. S100A4 was linked to cancer cell invasiveness and
metastasis in various human cancer types [27-31] and in vivo
cancer models [32-36]. Expression of the S100A4 protein is
positively correlated with breast cancer invasiveness of rodent
mammary carcinoma cells [37] and serves as an independent
prognostic marker that is highly significant for poor survival in
breast cancer patients [29]. Both, extracellular and intracellu-
lar functions of S100A4 contribute to tissue invasiveness. The
interaction with non-muscle myosin heavy chain IIA has been
extensively studied [38] and was associated with migratory
behaviour [39-41]. Extracellular S100A4 was also shown to
stimulate angiogenesis [32].
ERα-negative human breast cancers carry a high risk of meta-
static disease and have poor therapeutic responses [42,43].
The aim of the present study was to investigate the effect of
long-term relaxin exposure – mimicking the persistent expo-
sure to relaxin produced by breast carcinoma cells within the
cancer tissue – on in vitro cell migration and in vivo tumour
growth in an oestrogen-independent breast cancer cell model.
We propose a novel causal relationship between relaxin
expression, attenuated expression of S100A4 and reduced
tumour growth.
Materials and methods
Cell culture and relaxin exposure
MDA-MB-231 and T47D human breast cancer cells were cul-
tivated in HAM's F12 medium (Biochrom, Berlin, Germany)
substituted with 10% fetal calf serum (FCS), 2 mmol L-
glutamine (Gibco, Invitrogen, Burlington, ON, Canada), 6 ng/
ml insulin (Gibco; Invitrogen Corp, Burlington, ON, Canada),
3.75 ng/ml hydrocortisone (Sigma, Oakville, ON, Canada).
Stable MDA-MB-231/pIRES-EGFP-RLN2 and MDA-MB-231/
pIRES-EGFP vector control transfectants, referred to as MDA/
RLN2 and MDA/EGFP, respectively, were cultured in the
same medium supplemented with 800 μg/ml of the selective
antibiotic Geneticin (Gibco; Invitrogen Corp, Burlington, ON,
Canada). MCF7 cells were propagated in MEM with Earle's
salts (Biochrom AG, Berlin, Germany) supplemented with
10% FCS, 2 mmol L-glutamine, 1 nM sodium pyruvate (Gibco,
Invitrogen Corp, Burlington, ON, Canada) and 0.8 μg/ml insu-
lin (Gibco, Invitrogen). All cells were incubated in a 5% carbon
dioxide atmosphere at 37°C. The culture medium was
changed every second day and cells were passaged every two
to four days using accutase (PAA Laboratories GmbH, Linz,
Austria). Cells were frozen in 10% DMSO (dimethyl sulfoxide)
containing culture medium and stored in liquid nitrogen.
Before treatment with 100 ng/ml and 500 ng/ml RLN2 (Phoe-
nix Pharmaceuticals, Belmont, USA) in 1% FCS culture
medium, cells were adjusted to 1% FCS-containing culture
medium for 24 hours. For incubation periods longer than 24
hours, medium with fresh RLN2 at the same concentration
was changed daily.
Stable MDA-MB-231-pIRES transfectants
The generation of stable transfectants MDA/RLN2 and MDA/
EGFP was described previously [26]. A pre-proRLN2 pIRES-
EGFP construct was used and five MDA/RLN2 and two MDA/
EGFP clones were employed for this study.
Transcriptional analysis
Total RNA of the stable MDA/RLN2 and MDA/EGFP trans-
fectants was extracted using the Trizol reagent (Life Technol-
ogies, Karlsruhe, Germany) and the amount of total RNA was
determined by spectrophotometry at 260 nm/280 nm (Ultro-Available online http://breast-cancer-research.com/content/10/4/R71
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spec 3300 pro, Amersham, USA). Extraction of total RNA from
nude mouse tumour tissues was performed with the Trizol rea-
gent after homogenisation of the frozen tissue samples. Total
RNA (1 μg each) was used for the preparation of first strand
cDNA employing the superscript reverse transcriptase II
(Gibco, Berlin, Germany) and 100 ng/μl of random primer 50
(Invitrogen, Burlington, ON, Canada). For the amplification of
pre-proRLN2 and the partial coding sequence of human
RXFP1 intron-spanning oligonucleotide primers (Table 1)
were employed to preclude any genomic DNA amplification.
For semi-quantitative reverse transcriptase (RT) PCR analysis,
the 18S amplification in each cDNA preparation served as a
reference in determining relative cDNA levels per sample
using the BIO 1D software (LTF, Wasserburg, Germany). The
following conditions were used: 2 μl of cDNA, 2.5 μl of 10×
Advantage2 polymerase mix buffer (Clontech, Mountain View,
CA, USA), 100 μM of dNTP, 10 pmol of each primer (Table 1)
and 2 U Taq DNA-polymerase (Life Technologies, Invitrogen,
Canada) in a final volume of 25 μl. The amplification conditions
were optimised for each gene and consisted of 35 PCR cycles
for the respective target genes, with the exception of 18s
mRNA detection which was performed for 10 cycles (Table 1).
PCR cycles consisted of an initial denaturation for three min-
utes at 95°C, followed by several cycles of denaturation at
95°C (Table 1), annealing temperature specific for each
primer (Table 1), both for one minute each, an elongation step
for two minutes at 72°C and a final extension cycle for 10 min-
utes at 72°C. Amplicons were separated on a 2% agarose gel.
Kodak software (Kodak Digital Science 1D v.3.0.2.; Kodak,
Toronto, ON, Canada) was used to perform semi-quantitative
assessment of the specific PCR-products by densitometry
using the 18S amplicons as cDNA-specific internal standard.
Relaxin ELISA
MDA/RLN2 and MDA/EGFP transfectants were seeded at 1
× 105 cells/ml per well and incubated for 24 hours at 37°C in
a humidified carbon dioxide incubator. The cell culture super-
natant was collected and the concentration of secreted relaxin
was analysed by ELISA according to the manufacturer's pro-
tocol (ImmunoDiagnostic, Bensheim, Germany). The colour
reaction was measured at 450 nm with an ELISA reader (SLT
Labinstruments GmbH, Crailsheim, Germany).
cAMP assay
Intracellular cAMP levels were measured in MDA-MB-231
breast cancer cells. Cells were seeded at 1 × 104 cells per
well in 96 well plates. Before treatment, cells were incubated
with 1 mM 3-isobutyl-1-methyl-xanthine ([IBMX] Sigma, Stein-
heim, Germany) for two hours at 37°C. MDA-MB-231 cells
were then incubated with 100 ng/ml recombinant human
RLN2 or 100 μl/well of the supernatants of the MDA/RLN2
and MDA/EGFP transfectants, respectively, for 30 minutes at
37°C in the presence of 1 mM IBMX. These supernatants had
been collected from the stable transfectants (1 × 105 cells/
well) cultured overnight in six-well plates and centrifuged at
3000 × g for 10 minutes at 4°C to remove remaining cells.
Treatment with 10 μM Forskolin (Calbiochem-Novabiochem
Corp., San Diego, CA, USA) served as positive control for the
induction of cellular cAMP. Cells were harvested, washed and
lysed with cAMP extraction buffer and cAMP levels were
detected with the colourimetric cAMP Biotrak enzyme immu-
noassay according to the manufacturer's instructions (EIA,
Amersham, Freiburg, Germany). The reaction was stopped in
1 M H2SO4 and the product was measured at 450 nm in a
microplate ELISA reader (SLT Laboratory Instruments,
Gröding, Austria).
Bromodeoxyuridine assay
Cellular proliferation was determined using a competitive col-
ourimetric cell proliferation ELISA assay (Roche Diagnostics,
Mannheim, Germany) as described previously [4]. Briefly,
MDA/RLN2 and MDA/EGFP transfectants were seeded at 5
× 103 cells per 96 well in 100 μl culture medium and cultured
for 24 hours before adding 10 μl bromodeoxyuridine (BrdU)
Table 1
Oligonucleotide primers employed at melting temperatures (TM in °C) used to determine the expression of RLN2, human RXFP1 
relaxin receptor (RXFP1), S100A4 and 18S transcripts in human breast cancer cell lines and xenograft tumours.
Primer size primer sequence (5'-3') TM cycles
S100A4 289 bp sense – gaa ggc cct gga tgt gat ggt g 65°C 35
antisense – cat ttc ttc ctg ggc tgc tta tc
RLN2 485 bp sense – tct gtt tac tac tga acc aat tt 55°C 35
antisense – cat ggc aac att tat tag cca a
RXFP1 243 bp sense – ccc aat tct cta tac tct gac cac aag 65°C 35
antisense – tca tga ata gga att gag tct cgt tga tt
18S 344 bp sense – gtt ggt gga gcg att tgt ctg g 62°C 10
antisense – agg gca ggg act taa tca acg cBreast Cancer Research    Vol 10 No 4    Radestock et al.
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labelling solution for seven hours. The assay was performed
according to the manufacturer's instructions. The absorbance
was measured within five minutes in an ELISA reader (SLT
Laboratory Instruments, Gröding, Austria) at 450 nm/620 nm.
Cell cytotoxicity (MTT) assay
For cytotoxicity measurement, the NADH2-dependent cell via-
bility assay kit (Easy-for-you; Biomedica, Wien, Austria) was
used as previously described [4].
Luminometric ATP assay
Stable transfectants plated in 96 well plates at a density of
0.25, 0.5 and 1 × 104 cells/well were used as previously
described [4].
Motility assay
Cellular motility was evaluated in 24-well Transwell chambers
(Techno Plastic Products AG, Trasdingen, Switzerland) as
previously described [4]. Briefly, MDA-transfectants (1 × 104
cells) were plated on a polycarbonate filter insert with a pore
size of 8 μm (Thin Certs™-TC Inserts, Greiner bio-one, Ger-
many) in 200 μl culture medium with 1% FCS (upper cham-
ber). The lower chamber was filled with 500 μl culture medium
containing 1% FCS. After 24 hours, filter inserts were
removed and cells remaining on top of the filter were wiped off
with cotton swabs. Cells migrated through the membrane
pores to the underside of the membrane and were washed
with phosphate buffered saline (PBS), fixed in PBS/methanol
(Merck, Darmstadt, Germany) and stained with 0.1% toluidine
blue (Merck, Darmstadt, Germany) in 2.5% sodium carbonate
(Roth, Karlsruhe, Germany). Cells were counted under the
light microscope (Zeiss, Jena, Germany) in five separate high-
power fields per filter.
To determine the short-term paracrine effects of RLN2, MDA-
MB-231 cells were seeded on top of the filter and recom-
binant human RLN2 (rhRLN2, Phoenix, Burlingame, CA, USA)
was added at 100 ng/ml or 500 ng/ml to the upper and lower
chamber. To determine the paracrine effect of RLN2 secreted
by MDA/RLN2 stable transfectants on MDA-MB-231 cell
motility, MDA/RLN2 and MDA/EGFP (control) were plated in
the bottom chamber at 5 × 104 cells in 600 μl culture medium
with 1% FCS and cultured overnight at 37°C. MDA-MB-231
cells seeded at 1 × 104 cells on the top of the filter were then
inserted into the 24 wells containing the transfectants in the
lower chamber. After incubation for 24 hours, filters were
processed and migrated cells counted as described above.
To determine the long-term effects of rhRLN2 on cell motility,
MDA-MB-231 were incubated for seven days with 500 ng/ml
rhRLN2 before seeding on top of the filter with culture medium
containing 1% FCS and 500 ng/ml rhRLN2. Migrated cells
were counted after 24 hours. All experiments described here
were performed at least in triplicate and were expressed as
mean ± SEM.
In vitro invasion assay
For the assessment of the invasive abilities of MDA/RLN2
transfectants a modified 24-well Transwell assay was used as
previously described [4]. Briefly, polycarbonate, translucent fil-
ters with a pore size of 8 μm were coated with 1 μg/cm2 to 2
μg/cm2 laminin (from human placenta, Sigma, Oakville, ON,
Canada) and 0.8 mg/ml collagen A (from placenta, Biochrom
KG, Cambridge, UK). Cells were seeded on top of the coated
filters and the experiment was performed as described for the
motility assay. All experiments were performed at least in trip-
licate and were expressed as mean ± SEM.
siRNA knock-down experiments for RXFP1 and S100A4
Transcriptional knock-down was achieved by transient trans-
fections of MDA-MB-231 cells with specific small interfering
(si) RNAs to human RXFP1 (sense-r [GCAGUUACCUGCU-
UUGGAA]dTdT and antisense-r [UUCCAAAGCAG-
GUAACUGC]dAdG; Qiagen, Germany), human S100A4
(sense-GGGUGACAAGUUCAAGCUCtt and antisense-
GAGCUUGAACUUGUCACCCtc; Ambion, Cambridgeshire,
UK) and human negative control siRNA (sense-UUCUC-
CGAACGUGUCACGUdt dt and antisense-ACG
UGACACGUUCGGAGAAdt dt, Qiagen, Germany). The
siRNA at 150 nM (RXFP1 and negative control siRNA) and
200 nM (S100A4 and negative control siRNA) was com-
plexed with Lipofectamine-2000 (Invitrogen, Burlington, ON,
Canada) in serum-free OptiMem medium (Gibco, Invitrogen
Corp, Burlington, ON, Canada). MDA-MB-231 cells (1 × 105
cells) were seeded at 60% confluency in six-well plates and
incubated with the transfection mix for 24 hours at 37°C. The
transfection mix was replaced with normal medium. Cells
transfected with non-silencing siRNA and cells incubated with
Lipofectamine-2000 alone served as negative controls. Cells
were used in motility assays 48 hours after siRNA transfec-
tions. Total RNA was extracted with Trizol one, two and three
days after transfections.
Western blot analysis
For S100A4 protein extraction, cells were harvested, washed
with PBS (Ca2+-/Mg2+-free Biochrom AG, Germany) and
lysed with two times Laemmli extraction buffer under reducing
conditions [125 mmol/L Tris-HCl, pH 6.8, 4% SDS, 20% glyc-
erol, 10% mercaptoethanol (ME); 2% bromophenol blue; all
reagents from Sigma] containing a protease inhibitor cocktail
(Sigma, Oakville, ON, Canada). On a 15% SDS gel, 40 μl pro-
tein extracts were separated. After blotting onto PVDF mem-
branes (GE Healthcare, Buckinghamshire, UK) nonspecific
binding was blocked in PBS containing 0.1% Tween (PBS-T)
(EMD, San Diego, USA) and 3% BSA (Roth GmbH & Co,
Karlsruhe, Germany) for two hours at room temperature. A rab-
bit polyclonal antibody to S100A4 (Ab-8; Dunn Labortechnik,
Asbach, Germany) was diluted 1:500 in blocking buffer and
incubated overnight at 4°C. After thorough washing with PBS-
T a HRP (horseradish peroxidase)-conjugated secondary goat
anti-rabbit antibody (Dianova, Hamburg, Germany) atAvailable online http://breast-cancer-research.com/content/10/4/R71
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1:20,000 was employed for one hour at room temperature.
After washing with PBS-T, the proteins were visualised with
the ECL kit (Amersham, Piscataway, NJ, USA).
Tumour study in nude mice
MDA/EGFP and MDA/RLN2 (clones 19 and 23) at 2 × 107
cells/ml in medium without FCS were subcutaneously injected
into the abdominal region on both sides of each mouse. Male
nude mice (NMRI) of three weeks of age were used. This study
was approved by the animal ethics committee of the Martin
Luther University, Faculty of Medicine. Five mice were injected
per transfectant resulting in a maximum of 10 tumours to be
analysed for each transfectant. Tumour growth was measured
twice weekly. Primary tumour volumes were calculated
according to the mathematical formula for ellipsoid shapes.
After 60 days the mice were euthanased. Primary tumours
were fixed in 4% paraformaldehyde and embedded in paraffin
for histological examination and cryopreserved for RNA and
protein extraction.
Histological staining and immunohistochemistry
Paraformaldehyde-fixed and paraffin-embedded tumour tis-
sues were stained with haematoxylin and eosin for histological
analysis. Picrosirius red stain was performed according to the
method previously described [44]. For the detection of immu-
noreactive smooth muscle actin, a mouse monoclonal anti-
body (A5228, Sigma-Aldrich, Oakville, ON, Canada) was
used. Briefly, dewaxed 5 μm sections were equilibrated in
PBS-T. Endogenous peroxidase activity was inactivated with
3% hydrogen peroxide in methanol for 20 minutes at room
temperature. Nonspecific binding sites were blocked with
PBS-T containing 10% goat non-immune serum. Tissue sec-
tions were incubated overnight at 4°C with the mouse anti-
actin antibody diluted 1:500 in blocking buffer. After washing,
sections were incubated for one hour at room temperature
with a peroxidase-conjugated goat anti-mouse secondary anti-
body (Dianova, Hamburg, Germany) diluted 1:500 in PBS-T.
Specific binding was visualised with the peroxidase substrate
diaminobenzidine ([DAB] Pierce, Rockford, IL). Isotype control
mouse IgG (Sigma) at the same dilution served as a negative
control. For Ki67 staining, a rabbit monoclonal antibody (SP6,
Abcam, Cambridge, MA, USA) was used according to the
manufacturer's instructions using an alkaline phosphatase
detection method.
For the immunodetection of RXFP1 in MDA-transfectants,
cells were grown on coverslips and fixed in 4% paraformalde-
hyde. Sections were boiled in citrate buffer, blocked with 1%
BSA and 3% non-immune goat serum and incubated over-
night with a rabbit polyclonal antibody to RXFP1 (Phoenix
Pharmaceuticals, Burlingame, CA, USA) diluted 1:200 in
blocking buffer. A biotinylated goat anti-rabbit secondary anti-
body was applied (BA-1000, Vector Laboratories, Burlington,
ON, Canada) at 1:200 and specific staining was detected
with the ABC detection kit (Vector Laboratories, Burlington,
ON, Canada). Rabbit non-immune serum was used as nega-
tive control.
TUNEL assay
A TUNEL (dUTP nick end labelling) assay for the detection of
DNA fragmentation in apoptotic nuclei was performed on the
paraffin sections of six MDA/EGFP and six MDA/RLN2 nude
mouse tumours using the TACS.XL In situ Apoptosis Detec-
tion Kit (Trevigen Inc, Gaithersburg, MD, USA) according to
the manufacturer's instructions.
Results
Short-term exposure to relaxin causes increased cell 
motility in MDA-MB-231 human breast cancer cells and 
is dependent on RXFP1-signalling
Stable transfectants of the human ERα-negative breast cancer
cell line MDA-MB-231 over-expressing human RLN2 (MDA/
RLN2) were described previously to express increased
amounts of proRLN2 [26]. MDA/RLN2 transfectants
expressed transcripts for RLN2 and the relaxin receptor
RXFP1 (Figure 1a). Using a human relaxin-ELISA, these MDA/
RLN2 transfectants were shown to secrete more than 50
times the amount of RLN2 when compared with MDA/EGFP
controls (Figure 1b). The presence of RXFP1 protein in stable
MDA/EGFP and MDA/RLN2 transfectants was demonstrated
by immunohistochemistry (Figure 1d). Functionality of RXFP1
in MDA-MB-231 human breast cancer cells was determined
by the increase in intracellular cAMP production following
exposure to recombinant human RLN2 (rhRLN2; Figure 1c).
When exposed to the supernatants of MDA/RLN2 and MDA/
EGFP vector control clones, only the supernatant of MDA/
RLN2 containing secreted relaxin caused an increase in cAMP
production in MDA-MB-231 cells showing the secreted
proRLN2 to be bioactive (Figure 1c).
Two-chamber motility assays were performed to investigate
changes in cell motility with short-term relaxin treatment in
MDA-MB-231. A 24 hour exposure to 100 ng/ml and 500 ng/
ml rhRLN2 increased cell motility in MDA-MB-231 in a dose-
dependent manner (Figure 2a). When MDA-MB-231 cells
were exposed to the culture supernatants of stable MDA/
RLN2 and MDA/EGFP transfectants, only MDA-MB-231 cells
exposed to the supernatants of MDA/RLN2 transfectants
showed an increase in cell motility (Figure 2b) demonstrating
that secreted RLN2 also induced cell motility after 24 hours.
To exclude a relaxin-induced increase in cell proliferation as
being responsible for the increased number of migrated cells,
a BrdU assay was performed on MDA-MB-231 cells after 24
hour exposure to rhRLN2 and to the secreted RLN2 contained
in the supernatants of MDA/RLN2 clones. Our results demon-
strated that relaxin did not act as a growth factor in MDA-MB-
231 cells but, instead, caused reduced cell proliferation (Fig-
ure 2c).Breast Cancer Research    Vol 10 No 4    Radestock et al.
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The short-term increase in MDA-MB-231 cell motility in
response to RLN2 was mediated by the RXFP1 as determined
by specific siRNA knock-down experiments. Transient trans-
fections with a RXFP1 siRNA probe resulted in a significant
reduction of RXFP1 transcript levels in MDA-MB-231 (Figure
3a) and siRNA RXFP1-treated MDA-MB-231 failed to
respond with increased motility after 24 hours of incubation
with rhRLN2 (Figure 3b). In contrast, MDA-MB-231 cells
exposed to lipofectamine or transfected with a non-silencing
siRNA probe responded to rhRLN2 with increased motility
(Figure 3b).
Long-term exposure to relaxin decreases cell motility 
and in vitro invasiveness in MDA-MB-231 human breast 
cancer cells
To investigate whether long-term exposure to relaxin influ-
enced cell migration in MDA-MB-231 cells, we employed the
stable MDA/RLN2 and MDA/EGFP clones in cell motility and
Figure 1
Stable MDA/RLN2 transfectants secrete bioactive RLN2 and express functional RXFP1 Stable MDA/RLN2 transfectants secrete bioactive RLN2 and express functional RXFP1. (a) Reverse transcriptase polymerase chain reaction 
(RT-PCR) analysis was performed showing increased expression of RLN2 transcripts in all five MDA/RLN2 transfectants when compared with MDA/
EGFP-vector controls. Employing intron spanning primers encoding for the relaxin receptor RXFP1, a single transcript encoding RXFP1 was 
detected in both MDA/EGFP and MDA/RLN transfectants. 18S transcript levels were used as reference. (b) Secreted relaxin was quantified in the 
culture medium using a human relaxin-ELISA. MDA/RLN2 transfectants secreted significantly higher amounts of RLN2 compared with the MDA/
EGFP control; ** p ≤ 0.005. (c) A cAMPassay was used to determine the bioactivity of secreted RLN2. Intracellular cAMP concentration was deter-
mined in MDA-MB-231 cells following incubation with 100 ng/ml rhRLN, the culture supernatants of MDA/RLN2 clone 23 (SN-RLN-23) or of MDA/
EGFP (SN-EGFP) transfectants. Forskolin (10 μM) was used as positive control and untreated cells served as negative control. Induction of cAMP 
by secreted RLN2 and rhRLN2 demonstrates the presence of a functional RXFP1 receptor system in this cell line. Experiments were performed in 
triplicates; data were presented as mean ± SEM. Statistical significance was determined with student t-test and p ≤ 0.05 were marked with an aster-
isk. (d) The presence of RXFP1 protein in stable MDA/EGFP and MDA/RLN2 transfectants was detected by immunocytochemistry using a rabbit 
polyclonal antibody to human RXFP1. Positive staining for RXFP1 was obtained for all cell clones and shown here for (ai) MDA/EGFP, (bi) MDA/
RLN2-4 and (ci) MDA/RLN2-19. (di) A negative control using a rabbit non-immune serum did not result in any staining.Available online http://breast-cancer-research.com/content/10/4/R71
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migration assays. Four out of five MDA/RLN2 transfectants
with constitutive expression of RLN2 showed a reduction in
cell motility when compared with the MDA/EGFP vector con-
trols (Figure 4a). To determine whether the longer exposure
time to relaxin caused the observed decrease in cell motility,
we performed motility assays on MDA-MB-231 cells after
long-term treatment with rhRLN2 for seven days. Motility was
assessed following an additional 24 hour exposure to rhRLN2.
In contrast to MDA-MB-231 cells exposed to rhRLN2 for 24
hour only, cells treated with rhRLN2 for seven days were una-
ble to increase cell motility in response to an additional 24
hour exposure to rhRLN2 (Figure 4b). Thus, the increase in
cellular motility observed in untransfected MDA-MB-231 was
a temporary phenomenon during the first 24 hours of exposure
to relaxin and was not observed with long-term relaxin incuba-
tions and in MDA/RLN2 transfectants constitutively producing
relaxin. To determine whether relaxin altered the invasive
potential in MDA-MB-231, cell migration through components
of the extracellular matrix was tested. MDA/RLN2 transfect-
ants showed a reduced ability to invade through collagen A
(Figure 4c) and laminin (Figure 4d) when compared with the
MDA/EGFP vector controls.
To investigate whether a reduction in cell proliferation played
a role in the long-term effects of relaxin on MDA-MB-231 cells,
we performed BrdU and MTT proliferation assays on MDA/
RLN2 transfectants. Cell proliferation was reduced in one out
of five and three out of five MDA/RLN2 clones when tested in
a BrdU or MTT assay, respectively (Figures 5a, b) A lumino-
metric ATP assay was applied to MDA/RLN2 transfectants
and did not show any changes in metabolic activity compared
with MDA/EGFP vector controls (Figure 5c).
S100A4 is down-regulated by relaxin in breast cancer 
cells and S100A4 siRNA knock-down prevents relaxin-
induced increase in motility
The small calcium-binding protein S100A4 was down-regu-
lated to almost undetectable levels in all MDA/RLN2 stable
transfectants when compared with the untransfected MDA-
MB-231 cells or the MDA/EGFP vector controls (Figure 6a).
T47D human breast cancer cells exposed to 100 ng/ml and
500 ng/ml rhRLN2 for 72 hours also responded with a reduc-
tion in S100A4 protein (Figure 6b) with 500 ng/ml rhRLN2
already being effective after 48 hours of exposure. Transient
transfections with specific S100A4 siRNA probes were per-
formed to knock-down S100A4 protein in MDA-MB-231 cells
(Figure 7a). The aim was to investigate whether the observed
reduction in cell motility caused by long-term exposure to
rhRLN2 was mediated by the decrease in S100A4. S100A4
knock-down in MDA-MB-231 cells resulted in a reduction in
cell motility (Figure 7b). In addition, 500 ng/ml rhRLN2 failed
to increase cell motility after 24 hours of short-term exposure
after S100A4 knock-down (Figure 7b). MDA-MB-231 cells
transfected with a non-silencing siRNA probe or treated with
lipofectamine only were able to respond to RLN2 with an
Figure 2
Short-term exposure to exogenous RLN2 increases cell motility dose- dependently Short-term exposure to exogenous RLN2 increases cell motility 
dose-dependently. Relaxin-induced changes in MDA-MB-231 cellular 
motility were determined after 24-hour exposure using an 8 μm porous 
membrane migration assay. Cells which migrated through the 8 μm 
pores to the underside of the membrane were stained, five microscopic 
fields were counted for each filter and the results of three independent 
experiments are shown in the graph as mean ± SEM for (a) MDA-MB-
231 after incubation with 100 ng/ml and 500 ng/ml recombinant 
human (rh) RLN2 and (b) after exposure to secreted RLN2 from stable 
transfectants seeded in the lower chamber, shown here for MDA/EGFP 
and MDA/RLN2 clone 23. To assess proliferation, (c) MDA-MB-231 
cells were treated with the supernatant of MDA/EGFP control trans-
fectants (SN-EGFP) and of MDA/RLN2 transfectants (SN-RLN2) or 
with rhRLN2 at 100 ng/ml for 24 hours and proliferation was deter-
mined with a bromodeoxyuridine (BrdU) assay. rhRLN2 and secreted 
RLN2 slightly, but significantly reduced cell proliferation in MDA-MB-
231 cells. Experiments were performed in triplicates and data were pre-
sented as mean ± SEM. Statistical significance was assessed by (a) 
one-way ANOVA and with (b, c) student t-test using the SPSS soft-
ware package (SPSS GmbH, München, Germany). *p < 0.05; **p ≤ 
0.005.Breast Cancer Research    Vol 10 No 4    Radestock et al.
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increase in motility similar to untreated MDA-MB-231 cells
(Figure 7b). These results suggested that relaxin's short-term
effects on cell motility were dependent on S100A4 and that
the down-regulation of S100A4 following constitutive expo-
sure to RLN2 was responsible for the reduced cell motility and
migration in stable MDA/RLNs transfectants.
Long-term exposure to relaxin reduces xenograft tumour 
growth in vivo
Of the five stable MDA/RLN2 cell clones, MDA/RLN2 clone
19 and 23 and MDA/EGFP were injected subcutaneously in
nude mice and injection sites were monitored for a period of
60 days. MDA/EGFP tumours were palpable by week three
and MDA/RLN2 tumours by week four. The mice had to be
euthanized 60 days after injection of tumour cells because of
rapid growth of the MDA/EGFP control tumours. By contrast,
both MDA/RLN2 clones revealed much slower onset and pro-
gression of tumour growth as compared with MDA/EGFP con-
trol cells (Figure 8). All xenografts were removed at the end of
the experiment and found to be encapsulated. Animals were
inspected macroscopically and individual organs (brain, thy-
roid, submandibular glands, heart, lungs, diaphragm, liver,
intestines, pancreas, spleen, prostate, bladder and kidney)
were found to be free of metastases. To reveal bone metas-
tases, mouse skeletons were subjected to X-ray analysis but
also failed to show bone metastases in nude mice containing
MDA/RLN2 or MDA/EGFP xenograft tumours.
MDA/RLN2 xenograft tumours contain reduced S100A4 
protein levels and show histological changes in 
differentiation
Relaxin transcripts were exclusively detected in the MDA/
RLN2 xenografts (Figure 9a). Of the tumour tissues tested,
expression of the 10 kDa S100A4 protein was strongly
detectable in MDA/EGFP tumour tissues but was decreased
to almost undetectable levels in all MDA/RLN2 xenograft tis-
sues (Figure 9b) indicating the down-regulation of S100A4
during long-term exposure to RLN2 to be also effective in vivo.
Histological analysis of the xenograft tissues confirmed the for-
mation of encapsulated xenografts in all cases (data not
Figure 3
Relaxin's effect on motility is RXFP1-mediated Relaxin's effect on motility is RXFP1-mediated. RXFP1 relaxin receptor was down-regulated with 150 nM siRNA against RXFP1 (LGR7) in MDA-
MB-231 cells. Cells treated with the vehicle Lipofectamine 2000 only or transfected with 150 nM non-silencing small interfering (si) RNA were used 
as controls. (a) Semi-quantitative PCR analysis was performed with specific primers for RXFP1, shown here for 48 hours after transfection. (b) Motil-
ity of MDA-MB-231 cells seeded at 1 × 104 cells was assessed after RXFP1 knock-down with RXFP1 siRNA. The results of three independent 
experiments are shown in the graph as mean ± SEM, a two-way ANOVA analysis was performed with the SPSS software package and a p < 0.05 
was considered significant at the 95% confidence level as shown by the asterisks (**).Available online http://breast-cancer-research.com/content/10/4/R71
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shown) with MDA/EGFP and MDA/RLN2 xenografts contain-
ing areas with large tumour cells in the tumour periphery (Fig-
ure 10a, b) and necrotic areas in the centre of the tumours.
A TUNEL assay was performed to detect DNA fragmentation
but all sections of MDA/EGFP and MDA/RLN2 tumours were
devoid of apoptotic nuclei (data not shown). Picrosirius red
staining of collagen fibres showed small groups of tumour
cells surrounded by collagen in the MDA/RLN2 xenografts,
whereas MDA/EGFP tumours appeared less structured with
irregular and scarcely distributed collagen fibres (Figures 10c,
d). Of all xenografts, MDA/RLN2 tumours displayed a higher
number of cells positive for smooth muscle actin (Figures 10e,
f). Human lobulo-alveolar breast tissue was used as a positive
control and showed staining of myoepithelial cells surrounding
the breast epithelial cells (Figure 10G). Xenotransplants of
both MDA/RLN2 and MDA/EGFP clones revealed numerous
cells positive for the proliferation marker Ki67 (Figure 10h) in
the periphery of the tumours.
Discussion
To the authors' knowledge, the current study is the first to
describe distinct short-term and long-term effects of relaxin on
the cell motility in oestrogen-independent human breast can-
cer cells. The human breast cancer cell line MDA-MB-231
does not express ERα and, thus, is a suitable model to study
oestrogen receptor-independent effects of RLN2. MDA-MB-
231 cells produced very low endogenous levels of RLN2. The
relaxin receptor RXFP1 was expressed and functional as
determined by the induction of intracellular cAMP on exposure
to human recombinant RLN2. We employed MDA/RLN2 sta-
ble transfectants previously established in our laboratory and
Figure 4
Long-term exposure to relaxin decreases cell motility and in vitro invasiveness Long-term exposure to relaxin decreases cell motility and in vitro invasiveness. (a) MDA/RLN2 and MDA/EGFP transfectants were subjected 
to motility assays as described for Figure 2. (b) In contrast to a 24-hour short-term exposure, long-term incubation of MDA-MB-231 cells with 500 
ng/ml rhRLN for eight days did not cause changes in cellular motility with the number of migrated cells remaining unchanged when compared with 
controls (medium). Experiments were performed in triplicates and five microscopic fields were counted for each filter. The results are shown in the 
graph as mean ± SEM. (a, b) One-way ANOVA analysis was performed. **p < 0.005 when different from (a) MDA/EGFP or (b) medium treatment. 
MDA/RLN2 and MDA/EGFP transfectants were seeded on 8 μm porous filters coated with (c) collagen A and (d) laminin to assess in vitro invasive-
ness. Experiments were assessed as described for motility assays. The results of three independent experiments are shown in the graph as mean ± 
SEM. One-way ANOVA analysis was performed. **p < 0.005 when different from MDA/EGFP control.Breast Cancer Research    Vol 10 No 4    Radestock et al.
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shown to produce the 18 kDa pro-RLN2. These stable MDA/
RLN2 clones were shown here to secrete bioactive RLN2 and
to retain the expression of RXFP1. Thus, MDA/RLN2 trans-
fectants served as a cellular tool for the investigation of long-
term relaxin exposure.
We show here that a 24 hour short-term exposure to rhRLN2
dose-dependently increased cell motility, as did conditioned
media from MDA/RLN2 containing secreted RLN2. These
data confirm previous findings by us and other authors who
described relaxin as an enhancer of cancer cell motility/migra-
tion employing the human breast cancer cell lines MCF-7 and
SKBr3 [19], human prostate cancer cells PC3 [20], human
thyroid carcinoma cells [4] and human endometrial carcinoma
cell lines HEC-1B and KLE [3]. Our results with siRNA knock-
down of the relaxin receptor RXFP1 clearly demonstrated that
the relaxin-induced increase in cell motility was RXFP1-
dependent in MDA-MB-231 cells. The motility enhancing
effect was paralleled by a small but significant reduction in cell
proliferation demonstrating that relaxin did not act as mitogen
in MDA-MB-231 human breast cancer cells. Relaxin was pre-
viously described to lack a growth stimulatory effect on the
human endometrial cancer cell lines HEC-1B and KLE [3],
human MDA-MB-435 and canine CF33.MT breast cancer
cells [20]. Earlier in vitro studies found, that distinct relaxin
concentrations and exposure times had a differentiation-pro-
moting and growth-inhibitory effect of relaxin on MCF-7 cells
after seven days of incubation [21,22].
Figure 5
Long-term exposure to relaxin does not stimulate proliferation in MDA- MB-231 Long-term exposure to relaxin does not stimulate proliferation in 
MDA-MB-231. Proliferation of MDA/EGFP and MDA/RLN2 transfect-
ants was determined with (a) bromodeoxyuridine (BrdU) and (b) 
NADPH2-dependent MTT proliferation assays. Experiments were per-
formed in triplicates and shown in the graph as mean ± SEM. The t-test 
features of the SPSS 10.0 software were employed to calculate for sta-
tistical significance of MDA/RLN2 compared with MDA/EGFP. p < 
0.05 was marked in the graph as reduction (*) or as increase (#). **p < 
0.005. (c) A luminometric ATP assay was performed to assess the met-
abolic activity and no changes were determined in MDA/RLN2 com-
pared with MDA/EGFP clones.
Figure 6
S100A4 protein is down-regulated by relaxin S100A4 protein is down-regulated by relaxin. The 10 kDa S100A4 
protein was detected by Western blot analysis in cellular extracts of 
MDA-MB-231 cells, MDA/EGFP and MDA/RLN2 transfectants. (a) All 
MDA/RLN2 transfectants contained negligible levels of S100A4 pro-
tein when compared with MDA-MB-231 or MDA/EGFP vector controls. 
(b) In T47D cells, S100A4 protein was also down-regulated following 
48 hour and 72 hour exposure to 100 ng/ml or 500 ng/ml rhRLN2. 
Beta-actin detection was used to control for equal protein loading of 
the gels.Available online http://breast-cancer-research.com/content/10/4/R71
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We employed stable MDA/RLN2 transfectants to investigate
the long-term effects of constitutive exposure to relaxin, which
is most likely to be equivalent to the situation in breast
tumours. Surprisingly, MDA/RLN2 transfectants showed a
markedly reduced motility when compared with the EGFP-vec-
tor controls. Indeed, long-term exposure of MDA-MB-231 cells
to rhRLN2 for seven consecutive days before motility assays
also abolished the relaxin-induced increase in motility. This
decreased motility in MDA/RLN2 was not the result of a down-
regulation of RXFP1. Semi-quantitative RT-PCR analysis
showed no reduction in RXFP1 transcripts in MDA/RLN2
transfectants and RXFP1 protein was detected by immunocy-
tochemistry in MDA/RLN2 transfectants and MDA/EGFP vec-
tor controls. Interestingly, relaxin was previously shown to
increase RXFP1 transcripts in a dose- and time-dependent
manner in human decidual cells [45].
Earlier studies reported a relaxin-mediated enhanced cell
migration and extracellular matrix invasiveness with several dif-
ferent cancer cell lines [3,4,17-20]. Our results demonstrated
that long-term RLN2 exposure to relaxin negatively impacted
on the invasive capacity of MDA-MB-231 cells as assessed by
in vitro invasion assays using collagen A and laminin extracel-
lular matrix components. We did not use the tumour matrix
components of Matrigel to avoid the influence of numerous
growth factors contained within this tumour matrix. The
reduced invasive potential of MDA/RLN2 transfectants in vitro
suggested that the reduction in cellular motility through down-
regulation of S100A4 was the dominant mechanism of
relaxin's long-term effect on MDA-MB-231 breast cancer cells.
The small calcium-binding protein S100A4 was known to
enhance cell motility by interacting with non-muscle myosin II
and was described to selectively stimulate cell motility in
Figure 7
S100A4 siRNA knock-down abolishes relaxin's effect on cell motility S100A4 siRNA knock-down abolishes relaxin's effect on cell motility. Treatment of MDA-MB-231 cells with 200 nM S100A4 siRNA, but not 
with 200 nM non-silencing small interfering (si) RNA or Lipofectamine, resulted in down-regulation of S100A4 protein after 48 hours and 72 hours 
as shown here (a) after 48 hours. (b) When S100A4 siRNA treated MDA-MB-231 cells were subjected to 24 hours motility assays, relaxin was una-
ble to increase cell motility. In contrast, cells transfected with non-silencing siRNA probe and cells treated with lipofectamine only were able to 
respond to 500 ng/ml rhRLN2 with an increase in motility similar to untreated cells. The results of three independent experiments are shown in the 
graph as mean ± SEM. One-way ANOVA analysis was performed. **p < 0.005 for an increase compared with equivalent control and #p < 0.005 for 
a decrease compared with the non-treated control (MDA).Breast Cancer Research    Vol 10 No 4    Radestock et al.
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Figure 8
MDA/RLN2 transfectants show reduced tumour growth in vivo MDA/RLN2 transfectants show reduced tumour growth in vivo. 2 × 
107 cells/ml of the MDA/EGFP plasmid control transfectant and two of 
the MDA/RLN2 transfectants, MDA/RLN2-19 and MDA/RLN2-23, 
were injected subcutaneously in nude mice and the tumour growth rate 
(n = 10 tumours for each cell clone) was determined after 60 days of 
growth. All MDA/RLN2 xenografts showed slower tumour growth and 
smaller tumour sizes compared with the MDA/EGFP xenografts. Data 
are presented as mean ± SEM of tumour volume (mm3). A two-way 
ANOVA analysis was performed to determine statistical significance 
with p < 0.005 considered significant (**).
Figure 9
S100A4 protein is reduced in MDA/RLN2 nude mouse xenografts S100A4 protein is reduced in MDA/RLN2 nude mouse xenografts. 
(a) Total RNA was extracted from nude mice tumours and reverse tran-
scriptase polymerase chain reaction (RT-PCR) analysis was performed 
for human RLN2. Representative results are shown for three tumours 
grown in mice injected with MDA/RLN2 transfectants (R-T1, R-T2, R-
T3) and three tumours from mice injected with MDA/EGFP transfect-
ants (E-T1, E-T2, E-T4). Mouse liver was used as negative control tis-
sue. 18S transcript levels were used as reference. All MDA/RLN2 
xenografts contained RLN2 transcripts. (b) A representative Western 
analysis is shown for four MDA/RLN2 tumours (R-T1, R-T2, R-T3, R-
T4) demonstrating the down-regulation of S100A4 in all tumours when 
compared with tumours derived from MDA/EGFP transfectants (E-T1, 
E-T2). Beta-actin was used to control for protein loading of the gel.
Figure 10
MDA/RLN2 xenografts show immunohistological features of differentia- tion MDA/RLN2 xenografts show immunohistological features of dif-
ferentiation. Tissue sections from MDA/EGFP (left column) and MDA/
RLN2 tumours (right column) were stained with (a, b) haematoxylin and 
eosin and (c, d) picrosirious red showing smaller groups of tumour cells 
surrounded by collagen fibres in MDA/RLN2 tumours. Representative 
sections of the immunodetection of smooth-muscle actin are shown in 
(e) and (f). The primary antibody was substituted with an isotype control 
immunoglobulin and a representative control section is shown (insert in 
f). MDA/RLN2 tumours contained more smooth muscle actin positive 
cells then MDA/EGFP tumours. (g) A section of human mammary gland 
tissue was used as positive control and showed smooth muscle actin 
staining in the myoepithelial cells surrounding the alveoli. (h) Staining 
for the proliferation marker Ki67 revealed numerous positive nuclei in 
proliferative regions in the periphery of MDA/EGFP and MDA/RLN2 
tumours, an example is shown here for MDA/RLN2. Magnification: 
×400.Available online http://breast-cancer-research.com/content/10/4/R71
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mouse mammary carcinoma cell lines without increasing in
vitro invasiveness [39,46,47]. We had previously reported that
relaxin down-regulated S100A4 in MDA-MB-231 and in a sta-
ble MDA/RLN2 transfectant, thus, identifying S100A4 as a
novel target gene for relaxin in breast cancer cells [26]. Here,
we confirmed and extended this finding employing additional
MDA/RLN2 transfectants, all of which having almost undetec-
table levels of S100A4 protein. We were able to demonstrate
a similar down-regulation of S100A4 protein in ERα-positive
T47D human breast cancer cells after 48 hours and 72 hours
of RLN2 exposure. We have shown in this study that S100A4
siRNA knock-down abolished the ability of exogenous rhRLN
to up-regulate cell motility in MDA-MB-231 cells. These find-
ings demonstrated that the regulation of cell motility induced
by relaxin was dependent on S100A4 and emphasise the
importance of S100A4 as a relaxin target.
This down-regulation of the metastasis-promoting protein
S100A4 is of high clinical importance. S100A4, also named
metastasin, is a known promoter of tumour invasiveness and
growth [38], and was demonstrated to increase invasiveness
in mouse mammary carcinoma cells [37,48] and in a trans-
genic mouse model [34]. The expression of S100A4 in breast
tumour tissues serves a prognostic marker for poor patient
survival [29]. When injected subcutaneously in nude mice, all
xenograft tumours derived from MDA/RLN2 transfectants con-
tained reduced or almost undetectable levels of S100A4 pro-
tein when compared with the MDA/EGFP tumour tissues. This
demonstrated for the first time that S100A4 is a relaxin target
molecule in vitro and in vivo in human breast cancer cells.
However, we were unable to detect a negative regulation of
metastasis because all of the xenografts, including those of
MDA/EGFP, failed to show macroscopic metastases. The 60
day time interval for this investigation was most likely to be too
short for metastatic lesions to develop. The markedly reduced
tumour size in MDA/RLN2 xenografts may have been a result
of the reduced S100A4 production within the tumour cells.
Extracellular S100A4 was described to function as an ang-
iogenic factor as observed in S100A4 transgenic mice [32]
and  in vitro when tested on human cerebro-microvascular
endothelial cells [49]. Although MDA/EGFP and MDA/RLN2
xenografts showed large areas of necrotic tissue, on observa-
tion of haematoxylin and eosin-stained tumour sections there
was some indication that there might be fewer blood vessels
in MDA/RLN2 tumours. The reduced tumour size of MDA/
RLN2 xenografts is potentially a combined result of the
observed reduction in cell proliferation and the lack of an ang-
iogenic stimulus by S100A4 secreted from the tumour cells.
S100A4 was shown to bind to the tumour suppressor protein
p53 and to co-operate with wild type p53 in apoptosis induc-
tion [50]. TUNEL assays performed on the xenograft sections
failed to detect apoptotic nuclei in our MDA/RLN2 xenograft
model with reduced tumour growth. Instead, relaxin may
directly stimulate cell differentiation in vivo. We have detected
an increased number of cells with positive staining for smooth
muscle actin suggesting the presence of myoepithelial cells in
MDA/RLN2 tumours. In addition, the collagen distribution in
MDA/RLN2 tumours as determined by picrosirious red stain-
ing showed collagen to be more regularly distributed among
strands of tumour cells in MDA/RLN2 tumours when com-
pared with MDA/EGFP tumours. This may suggest a higher
epithelial differentiation and organisation in the MDA/RLN2
tumours. Earlier studies showed that human MCF-7 breast
cancer cell xenografts in oestrogen-treated nude mice
revealed an increased differentiation response to systemic
application of relaxin with the formation of differentiated epi-
thelial- and myoepithelial-like cells [23]. Taken together, these
data suggest that long-term exposure to relaxin may trigger dif-
ferentiation-promoting and anti-invasive changes in breast
cancer cells.
Conclusion
In conclusion, the in vitro and  in vivo down-regulation of
S100A4 identifies a new and potentially clinically relevant
property of relaxin in human breast cancer. Further studies are
ongoing to identify the signalling pathways involved in the
relaxin-induced regulation of S100A4.
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